<DOC>
	<DOCNO>NCT00671658</DOCNO>
	<brief_summary>The goal clinical research study learn intensive chemotherapy ( monoclonal antibody therapy patient ) give 8 course 5 6 month follow monthly maintenance chemotherapy 2 Â½ year improve cure acute lymphoblastic leukemia ( ALL ) lymphoblastic lymphoma .</brief_summary>
	<brief_title>Modified Hyper-CVAD ( Cyclophosphamide , Vincristine , Adriamycin , Dexamethasone ) Program Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>The modified hyper-CVAD regimen combination chemotherapy drug include cyclophosphamide , vincristine , Adriamycin , dexamethasone pegylated asparaginase give together one `` course '' treatment . This alternate course combination chemotherapy drug methotrexate , cytarabine ( ara-C ) , pegylated asparaginase . Rituximab protein ( monoclonal antibody ) attach surface leukemia lymphoma cell , marker , call `` CD20 '' . Before treatment start , participant complete physical exam , include blood ( 8 teaspoon ) test . A chest X-ray may take . CT scan may take need . A bone marrow sample take large needle hipbone . Women able child must negative blood pregnancy test . An ECG ( trace heart ) cardiac scan echocardiogram may take check heart function . Participants receive 2 kind intensive chemotherapy course total 8 course long able tolerate . Chemotherapy course give large vein central venous catheter ( plastic tube usually place collarbone ) long-line catheter ( plastic tube usually place upper arm ) . During treatment , participant physical exam undergo blood test ( 1 tablespoon ) least twice week . After first course chemotherapy , test do treatment repeat check response . In patient acute lymphoblastic leukemia lymphoblastic lymphoma marrow disease , bone marrow sample repeat 2 3 week begin treatment check response . Course 1 ( odd course ) start give rituximab vein 6 hour Day 1 Day 11 patient whose leukemia lymphoma express CD20 . Participants receive drug acetaminophen ( Tylenol ) diphenhydramine hydrochloride ( Benadryl ) 30-60 minute dose rituximab . This do lessen risk fever , chill , allergic reaction . Usually , first dose rituximab require 6 8 hour complete . If side effect occur infusion , participant observe additional 2 hour rituximab give . Then , cyclophosphamide give described . Other participant CD20 marker start Course 1 cyclophosphamide give vein 2-3 hour every 12 hour . This give 6 dos 3 day ( Days 1,2 , 3 ) . Pegylated asparaginase give vein 30 minute Day 1 . Adriamycin give vein 24 hour Day 4 . Vincristine give vein 15 30 minute Days 1 11 . Dexamethasone ( steroid ) give mouth vein Days 1 4 11 14 . Pegfilgrastim ( growth colony stimulate factor ) give course chemotherapy finish . It give help rapid recovery white blood cell normal marrow . Pegfilgrastim inject skin within 72 hour completion cycle chemotherapy . Filgrastim , shorter active form pegfilgrastim may use instead add later need . Treatment protect brain give inside spinal use lumbar puncture ( spinal tap ) chemotherapy , include methotrexate around day 2 cytarabine ( ara-C ) day 7 course . This do decrease risk leukemia lymphoma develop . If leukemia lymphoma spinal fluid time first spinal tap , treatment give frequently . For patient age 60 year old , first course chemotherapy give protective isolation room decrease risk infection ( ) . During Course 2 , participant whose leukemia express CD20 receive rituximab infusion 4 hour Days 1 8 . Other participant CD20 leukemia cell start methotrexate vein 24 hour Day 1 . Cytarabine ( ara-C ) give vein 2 hour every 12 hour 4 dos ( Days 2 3 ) . Vincristine give vein 15 30 minute Days 1 8 . Pegylated asparaginase give vein 30 minute Day 4 5 methotrexate clear ( checked blood test ) . Citrovorum factor ( leucovorin ) , antidote side effect methotrexate , give vein mouth 2-3 day ( Day 2 ) . Pegfilgrastim give Course 1 ( 24-72 hour chemotherapy finish ) . The treatment protect brain inside spinal fluid give Course 1 Days 2 7 . The rest chemotherapy switch hyper-CVAD pegylated asparaginase ( Courses 3 , 5 , 7 ) methotrexate , cytarabine ( ara-C ) , vincristine , pegylated asparaginase ( Courses 4 , 6 , 8 ) complete total 8 course . Participants whose leukemia express CD20 receive total 12 dos ( 2 per first four course , one last four course ) rituximab . After 8 course , patient lymphoblastic lymphoma enlarge lymph gland mediastinum may receive radiation chest . Those participant need radiation proceed monthly maintenance chemotherapy . This include daily 6-mercaptopurine take mouth , weekly methotrexate vein mouth , monthly vincristine vein , dexamethasone mouth 5 day every month . Participants lymphoblastic lymphoma start maintenance chemotherapy finish radiation . Maintenance chemotherapy give total 30 month , interrupt 2 period intensive chemotherapy course . The first six month maintenance program start first hyper-CVAD ( like Course 1 ) except without pegylated asparaginase ) . The following month , participant receive methotrexate vein Day 1 , vincristine vein Day 1 , pegylated asparaginase vein Day 2 . Participants receive sequence 2 chemotherapy course 18 month maintenance program . Participants CD20 marker receive rituximab maintenance chemotherapy ( vincristine month 1 , 3 , 6 , 7 , 10 , 13 , 18 &amp; 19 ) . After one two course therapy , response treatment evaluate . If leukemia lymphoma responding , therapy continue . Participants take study leukemia lymphoma start get bad . After completion treatment , participant complete physical exam , include blood test ( 8 teaspoon ) . If need , chest X-ray CT scan do . A bone marrow sample take large needle . Patients return every 3 6 month checkup , include blood test bone marrow aspiration . X-rays may repeat need . An Ommaya reservoir may also place surgically route treat leukemia brain decrease risk leukemia patient difficulty spinal treatment . An Ommaya reservoir tube insert skin scalp enters spinal fluid cavity brain . Treatment give inpatient basis 8 intensive cycle chemotherapy , indicate clinical condition . The maintenance treatment give outpatient may give inpatient need . This investigational study . All drug commercially available . Their use together study investigational . About 280 patient take part study . All enrol M. D. Anderson Cancer Center .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Newly diagnose , previously untreated ALL lymphoblastic lymphoma , achieve CR one course induction chemotherapy . 2 . Failure one induction course chemotherapy eligible , patient analyze separately . 3 . All age eligible . 4 . Zubrod performance less equal 3 5 . Adequate liver function ( bilirubin &lt; /= 3.0 mg/dl unless consider due tumor ) renal function ( creatinine &lt; /= 3.0 mg/dl , unless consider due tumor ) . 6 . Adequate cardiac function assess history physical examination . 7 . No active coexisting malignancy life expectancy le 12 month due malignancy . 1 ) N/A</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>HYPER-CVAD</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>ALL</keyword>
	<keyword>Remission Duration</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Asparaginase</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Leukine</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Vincristine</keyword>
</DOC>